Skip to main content
Log in

No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar®/Mimpara®)

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Objective

Cinacalcet (cinacalcet HCl; Sensipar®/Mimpara®) is a calcimimetic that is a treatment for secondary hyperparathyroidism in patients with renal failure. The objective of this study was to assess the effects of renal function and dialysis on the pharmacokinetics and pharmacodynamics of cinacalcet.

Methods

Two open-label, single-dose (75mg) studies of cinacalcet were performed: study 1 examined 36 subjects who had renal function ranging from normal to requiring haemodialysis, and study 2 examined ten subjects who were receiving continuous ambulatory peritoneal dialysis. Cinacalcet plasma concentrations were determined using a liquid chromatography-mass spectrometry/mass spectrometry assay. Cinacalcet pharmacokinetics were assessed using noncompartmental analyses.

Results

Following single-dose administration of cinacalcet, there was no evidence of increasing exposure with increasing degree of renal impairment, and the pharmacokinetic profile was similar for all subjects regardless of whether they were receiving haemodialysis (no difference on dialysis or nondialysis days detected) or peritoneal dialysis. Protein binding of cinacalcet, determined in study 1 only, was similar in all groups and the level of renal function did not affect the pharmacodynamics (as determined by intact parathyroid hormone and calcium levels). No serious adverse events occurred during either study.

Conclusion

The degree of renal impairment and mode of dialysis do not affect the pharmacokinetics or pharmacodynamics of cinacalcet. Therefore, the dose of cinacalcet does not need to be altered for degree of renal impairment or dialysis modality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table III

Similar content being viewed by others

References

  1. Nemeth EF. Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles in bone biology. San Diego (CA): San Diego Academic Press, 1996: 1019–35

    Google Scholar 

  2. Garrett JE, Capuano IV, Hammerland LG, et al. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995; 270(21): 12919–25

    Article  PubMed  CAS  Google Scholar 

  3. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14(3): 575–83

    Article  PubMed  CAS  Google Scholar 

  4. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63(1): 248–54

    Article  PubMed  CAS  Google Scholar 

  5. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13(4): 1017–24

    PubMed  CAS  Google Scholar 

  6. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350(15): 1516–25

    Article  PubMed  CAS  Google Scholar 

  7. Voigts A, Felsenfeld AJ, Andress D, et al. Parathyroid hormone and bone histology: response to hypocalcemia in osteitis fibrosa. Kidney Int 1984; 25(2): 445–52

    Article  PubMed  CAS  Google Scholar 

  8. Wang M, Hercz G, Sherrard DJ, et al. Relationship between intact 1–84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995; 26(5): 836

    Article  Google Scholar 

  9. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4): 607–17

    Article  PubMed  CAS  Google Scholar 

  10. Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58(1): 396–9

    Article  PubMed  CAS  Google Scholar 

  11. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35(6): 1226–37

    Article  PubMed  CAS  Google Scholar 

  12. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342(20): 1478–83

    Article  PubMed  CAS  Google Scholar 

  13. Rix M, Andreassen H, Eskildsen P, et al. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 1999; 56(3): 1084–93

    Article  PubMed  CAS  Google Scholar 

  14. Vanholder R, De Smet R, Ringoir S. Factors influencing drug protein binding in patients with end stage renal failure. Eur J Clin Pharmacol 1993; 44 Suppl. 1: S17–21

    Article  PubMed  Google Scholar 

  15. Guidance for industry: pharmacokinetics in patients with impaired renal function: study design, data analysis, and impact on dosing and labelling. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research, 1998 May

  16. Harris RZ, Padhi D, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet HCI in hemodialysis patients at doses up to 200mg once daily. Am J Kidney Dis 2004; 44(6): 1070–6

    Article  PubMed  CAS  Google Scholar 

  17. Ings RMJ. Pharmacokinetics and its application to drug development. In: Illing HPA, editor. Xenobiotic metabolism and disposition: the design of studies on novel compounds. Boca Raton (FL): CRC Press, 1989: 99–146

    Google Scholar 

  18. Padhi D, Harris R, Salfi M, et al. The pharmacokinetics of cinacalcet HCl are not altered by renal impairment or mode of renal replacement therapy [abstract]. World Congress of Nephrology Meeting; 2003 Jun 8–12; Berlin

    Google Scholar 

  19. Padhi D, Harris R, Salfi M, et al. Cinacalcet HCl absorption is not affected by coadministration of medications commonly prescribed to chronic kidney disease patients (pantoprazole sodium, sevelamer HCl, and calcium carbonate) [abstract]. American Society of Nephrology Meeting; 2003 Nov 12–17; San Diego

    Google Scholar 

  20. Sensipar® package insert. Thousand Oaks (CA): Amgen Inc., 2004

Download references

Acknowledgements

This work was funded by Amgen Inc., and all authors are employees of Amgen Inc. The authors would like to thank Thomas Marbury, Ramon Vargas and Marshall Sack for their contributions to this research. The manuscript is an accurate representation of the study results.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Desmond Padhi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Padhi, D., Harris, R.Z., Salfi, M. et al. No Effect of Renal Function or Dialysis on Pharmacokinetics of Cinacalcet (Sensipar®/Mimpara®). Clin Pharmacokinet 44, 509–516 (2005). https://doi.org/10.2165/00003088-200544050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200544050-00004

Keywords

Navigation